Sunshine Biopharma majority owner approves reverse split up to 1-for-20

Sunshine Biopharma Inc.

Dr. Steve N. Slilaty, CEO, holding ~97% voting power, approved reverse split via written consent on Sept 15, 2026.
Board authorized to effect split at ratio up to 1-for-20, with exact whole-number ratio at board's discretion.
Consent effective 20 days after definitive information statement mailed to stockholders.
Split applies to common stock (SBFM); warrants (SBFMW) also listed on Nasdaq.
No timeline for board decision; action allows flexibility to meet listing requirements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.